AbbVie Inc.

AbbVie Inc.

5,486.00
MXN
-27.00
(-0.49%)
105.40EPS
45.19P/E
8.44TMarket Cap
Feb 03Next Earn
AbbVie Inc.
BMV:ABBV
(Mexican Stock Exchange)

Recent

price

5,486.00

P/E

ratio

45.19

div

yld

2.26%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
9.68
10.79
11.66
11.84
12.54
14.2
16.1
17.72
22.15
22.49
25.95
31.78
32.81
30.76
31.91
34.57
37.35
Revenue per Share
2.59
2.12
3.34
2.6
1.11
3.2
3.74
3.33
3.85
5.33
2.62
6.53
6.69
2.75
2.42
2.39
5.85
Basic EPS, GAAP
2.8
3.65
3.81
3.64
1.85
4.35
4.12
5.92
8.65
8.64
9.51
12.44
13.71
12.49
10.1
10.07
10.68
Free Cash Flow per Basic Share
- -
- -
- -
1.61
1.67
2.05
2.33
2.58
3.77
4.3
4.37
5.24
5.68
5.97
6.25
6.59
6.87
Dividend per Share
9.94
7.55
2.13
2.83
1.09
2.45
2.91
3.2
-5.71
-5.53
7.41
8.71
9.75
5.87
1.88
-1.85
-2.59
Book Value per Share
3.68
1.85
-3.22
-2.32
-3.54
-17.97
-24.91
-24.02
-30.66
-28.69
-58.31
-52.55
-46.54
-43.91
-51.95
-51.79
-56.03
Tangible Book Value per Share
1,616
1,616
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,769
1,766
1,765
1,769
1,767
Basic Weighted Avg Shares
15,638
17,444
18,380
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
66,014
Sales/Revenue/Turnover
30.16
20.75
31.65
30.14
17.09
32.97
36.43
33.83
19.49
39.03
24.81
31.89
32.41
24.92
21.11
32.85
35.98
Operating Margin (%)
1,184
1,272
1,150
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
7,667
Depreciation Expense
4,178
3,433
5,275
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
10,342
Net Income, GAAP
13.61
6.41
7.86
22.58
25.12
22.59
24.49
31.29
- -
6.46
- -
11.09
12.11
22.03
- -
35.83
19.24
Effective Tax Rate (%)
26.72
19.68
28.7
21.97
8.89
22.5
23.22
18.82
17.36
23.69
10.08
20.54
20.39
8.95
7.59
6.91
15.67
Profit Margin (%)
4,457
1,457
8,578
10,969
4,688
5,420
6,406
4,582
-294
33,934
-4,488
-7,266
-1,075
-4,839
-13,167
-14,227
-5,622
Working Capital
- -
32
14,630
14,292
10,538
29,240
36,440
30,953
35,002
62,975
77,554
64,189
59,135
52,194
60,340
58,941
72,230
LT Debt
15,703
11,932
3,363
4,492
1,742
3,945
4,636
5,097
-8,446
-8,172
13,097
15,436
17,287
10,397
3,364
-3,228
-4,538
Total Equity
- -
24.76
34.74
22.93
14.22
22.3
18.3
15.63
- -
26.89
- -
16.66
18.44
13.23
- -
14.35
24.06
Return on Invested Capital (%)
- -
24.8
34.63
22.79
11.66
21.78
17.49
14.53
- -
21.13
- -
14.31
15.97
8.76
- -
9.02
17.88
Return on Capital (%)
- -
24.85
68.98
105.11
56.91
180.9
138.75
109.09
- -
- -
- -
81.04
72.48
35.22
62.52
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8,326
8,341
8,673
LT Borrowings
64,532
62,481
72,230
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,767
1,767
1,768
Market Capitalization
370,963
446,126
467,398

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
33,529
33,669
37,480
Cash, Cash Equivalents & STI
9,391
6,569
10,774
Accounts Receivable, Net
12,479
13,824
13,509
Inventories
5,049
5,127
5,305
Total Current Liabilities
42,100
41,642
43,102
Payables & Accruals
33,774
33,301
34,429
ST Debt
8,326
8,341
8,673
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.54%
-54.72%
-195.96%
Free Cash Flow
11.73%
2.59%
-0.09%
Net Income, GAAP
8.96%
16.09%
-1.22%
Sales/Revenue/Turnover
10.94%
6.37%
8.57%
Total Cash Common Dividend
13.82%
8.75%
5.73%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,310
14,462
14,460
15,102
56,334
2025
13,343
15,423
15,776
16,618
61,160
2026
15,002
16,990
17,404
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.78
0.78
0.88
-0.01
2.42
2025
0.73
0.53
0.11
1.03
2.39
2026
0.39
2.04
2.39
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.56
1.56
1.56
6.25
2025
1.65
1.65
1.65
1.65
6.59
2026
1.75
1.74
1.74
- -
- -
Business
AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.

Company News

  • How Retirees Can Turn $175,000 Into Passive Income With These 4 Dividend Stocks

  • Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

  • AbbVie Inc. $ABBV Stock Sold by BCV Asset Management Inc.

  • 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%

  • 5 High-Yield Dividend Stocks That Could Beat a 5% Treasury Yield

  • 3 Dividend Stocks Built for a Market Priced Like It's 1999

  • How Did AbbVie's Immunology Franchise Fare in Q3?

  • 3 Pharmaceutical Stocks That Offer Safety and Growth

  • Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year

  • ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?

  • 3 Legacy Health Care Dividend Stocks That Never Go Out of Style

  • AbbVie Inc. $ABBV Stock Bought by AlphaCore Capital LLC

  • CenterBook Partners LP Purchases New Stake in AbbVie Inc. $ABBV

  • Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

  • Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

  • How Much Do You Need in a Roth IRA at 58 to Replace a $120,000 Salary Tax-Free?

  • $600,000 in Dividend Stocks: How a Roth IRA Could Save You $4,460 a Year

  • 2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY

  • 5 High-Yield Dividend Stocks Paying Up to 6% With Payouts Built to Last

  • Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?